XRCC1 and lung cancer: The result involving 8,876 lung cancer patients and 11,210 controls revealed that XRCC1 Arg194Trp polymorphism was not associated with lung cancer risk [(OR = 0.97, 95 %CI = 0.92–1.03) for Trp vs. Arg; (OR = 0.92, 95 % CI = 0.85–0.98) for ArgTrp vs. ArgArg; (OR = 1.07, 95 % CI = 0.92–1.23) for TrpTrp vs. ArgArg; (OR = 0.93, 95 % CI = 0.87–1.00) for (TrpTrp + ArgTrp) vs. ArgArg; and (OR = 1.08, 95 % CI = 0.94–1.25) for TrpTrp vs. (ArgTrp + ArgArg)].